The relationship between serum anti-cyclic citruline peptide antibody and disease in patient with lung cancer

INTRODUCTION AND AIM: Lung cancer is uncontrolled proliferation of abnormal cells in the lungs. The symptoms of lung cancer may be due to; cancer itself, spread to distant organs or hormone-like substances secreted by cancer cells. Paraneoplastic syndromes are a group of symptoms and signs that are not associated with invasion, obstruction, or metastasis in the remote areas and may be helpful in the early detection of malignant disease. In this study, it was aimed to reveal a possible relationship between serum Anti-CCP antibody level and disease type and and stage in patients with lung cancer. MATERIALS AND METHODS: Fifty patients with lung cancer diagnosed in the Departments of Internal Medicine, Medical Oncology, Chest Diseases and Radiation Oncology were included in the study. During the routine control of the patients, the blood in red tubes was collected and stored at -20 ° C after being studied in the laboratory. The control group was selected from the patients of similar age and sex who were applied to the internal medicine polyclinic because of various health problems (DM, HT, etc.). After collection of the blood of the patient and the control group was completed, serum Anti-CCP level was measured by ELISA method. All cases were questioned for smoking history, alcohol use, chemical exposure, previous medical conditions (type 2 DM, HT, COPD, asthma, sarcoidosis, RA) and tumor history (tumor presence, chemotherapy, radiotherapy and family history of malignant disease). RESULTS: In our study, the median age of the lung cancer patients was 63 and the control group was 68. Both the patient and control group had 40 males and 10 females. 36 of lung cancer patients (72%) had a history of smoking, we couldn't reach 11 (22%) of lung cancer patient's smoking history. 1 (2%) patient never smoked. There were 38 patients with NSCLC and 11 patients with SCLC in the patient group. In one patient, the coexistence of the adenocancer subtype of SCLC and NSCLC was detected. In the patient group, 16 of patients with NSCLC were stage 4 (32%), 15 were stage 3 (30%), 4 were stage 2 (8%), 2 were stage 1 (4%), and 2 patient's stage wasn't known (4%). Six patients (12%) were widespread stage in SCLC patients and 5 patients (10%) were in the limited stage group. When the anti-CCP values of patients were compared with these demographic data, no significant result was obtained. CONCLUSION: According to our results, anti-CCP was not detected as a sign that could be used in the diagnosis and follow-up of lung cancer. However, in some studies, some signs of citrullination were found to be significantly associated with lung cancer. Therefore, there is a need for wider, prospective and planned work to be done with anti-CCP. KEYWORDS: Lung cancer; anti-CCP; paraneoplastic syndrome